Results 21 to 30 of about 256,662 (267)
Arquivos Brasileiros de Cardiologia, 2001 OBJECTIVE: The association between cytokines and troponin-I with cardiac function after cardiac surgery with cardiopulmonary bypass remains a topic of continued investigation.
Neverton Savaris +2 more
doaj +1 more source
TRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitro. [PDF]
PLoS ONE, 2011 Signaling by Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) and Fas ligand (FasL) has been proposed to contribute to the chemosensitivity of tumor cells treated with various other anti-cancer agents.
Christina Menke +6 more
doaj +1 more source
Dentistry Journal, 2022 Soluble tumor necrosis factor receptors 1 and 2 (sTNF-R1 and sTNF-R2) are reported to protect against excessive TNF-α, a primary mediator of systemic responses to infection.
Ryota Kibune +4 more
doaj +1 more source
Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy [PDF]
Journal for ImmunoTherapy of Cancer, 2014 With the success of ipilimumab and promise of programmed death-1 pathway-targeted agents, the field of tumor immunotherapy is expanding rapidly. Newer targets for clinical development include select members of the tumor necrosis factor receptor (TNFR) family.
Schaer, David A +2 more
openaire +2 more sources
Plasma Levels of Tumor Necrosis Factor α and Soluble Tumor Necrosis Factor Receptors in Patients With Narcolepsy [PDF]
Archives of Internal Medicine, 2006 Narcolepsy is a disabling sleep disorder characterized by excessive daytime sleepiness, cataplexy, hypnagogic hallucinations, and sleep paralysis. Recent studies suggest that the immune system might play a pathogenic role pointing to a possible involvement of inflammatory cytokines.We investigated a sample of 30 patients with narcolepsy in comparison ...
Himmerich, Hubertus +9 more
openaire +3 more sources
Tumor necrosis factor antagonists: structure, function and tuberculosis risks [PDF]
Einstein (São Paulo), 2009 New therapeutic options bring new problems and also new knowledge about disease mechanisms. Ten years ago the first antagonist to tumor necrosis factor was first used to treat inflammatory diseases and the use of anti-cytokines has proved to be a ...
Jacyr Pasternak
doaj
Analytical Cellular Pathology, 2010 Background: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) initiates apoptosis in tumor cells upon binding to its cognate agonistic receptors, death receptors 4 and 5 (DR4 and DR5). The activity of the insulin-like growth factor 1 (IGF-1)
Bodvael Pennarun +5 more
doaj +1 more source
Intrinsic cardiac adrenergic cells contribute to LPS-induced myocardial dysfunction
Communications Biology, 2022 Yang et al report that intrinsic cardiac adrenergic cell-derived norepinephrine promotes myocardial dysfunction in response to LPS. They demonstrate norepinephrine produced by these cells activated β1-adrenergic receptors on cardiomyocytes increasing the
Duomeng Yang +11 more
doaj +1 more source
Frontiers in MicrobiologyIntroductionThe proteolytic activity of A Disintegrin and Metalloproteinase 17 (ADAM17) regulates the release of tumor necrosis factor (TNF) and TNF receptors (TNFRs) from cell surfaces.
José Alberto Choreño-Parra +30 more
doaj +1 more source
Molecular Pain, 2016 Despite mu opioid receptor agonists are the cornerstones of moderate-to-severe acute pain treatment, their effectiveness in chronic pain conditions is controversial.
Nunzio Vicario PhD (cand) +6 more
doaj +1 more source